{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:13:15Z","timestamp":1790791995388,"version":"4.1.0"},"reference-count":25,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013831","name":"University of Medicine and Pharmacy of Craiova","doi-asserted-by":"publisher","award":["26\/725\/9\/25.07.2024"],"award-info":[{"award-number":["26\/725\/9\/25.07.2024"]}],"id":[{"id":"10.13039\/501100013831","id-type":"DOI","asserted-by":"publisher"}]},{"award":["26\/725\/9\/25.07.2024"],"award-info":[{"award-number":["26\/725\/9\/25.07.2024"]}],"id":[{"id":"https:\/\/ror.org\/031d5vw30","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolically dysfunction-associated steatotic liver disease (MASLD) complicated by type 2 diabetes mellitus (T2DM) represents a clinically aggressive phenotype associated with accelerated hepatic fibrosis progression. The interplay among oxidative stress, systemic inflammation, and the risk of hepatic fibrosis in this context remains incompletely characterised. We conducted a single-centre observational study enrolling 110 adult MASLD patients, stratified into two groups: Group 1 (G1, n = 20), patients with concurrent T2DM, followed longitudinally at three successive time points, and Group 2 (G2, n = 90), non-diabetic controls. Serum oxidative stress biomarkers were assessed using malondialdehyde (MDA) and 8-isoprostaglandin F2\u03b1 (8-iso-PGF2\u03b1). Systemic inflammatory status was quantified through the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR). Hepatic fibrosis risk was estimated using the FIB-4 index. Diabetic MASLD patients exhibited significantly elevated levels of 8-iso-PGF2\u03b1 (p = 0.014) and NLR (p = 0.016) compared with controls, indicating greater oxidative membrane damage and systemic neutrophilic inflammation. A robust inverse correlation between PLR and FIB-4 was observed across all analytical strata (combined cohort: Spearman r = \u22120.680, p &lt; 0.001). MLR emerged as the only independent predictor of MDA in G1 (\u03b2 = 841.78, p = 0.013). Longitudinal analysis demonstrated biomarker stability over time, except for a significant increase in ALT from T1 to T2 (p_adj = 0.014). These findings support the clinical utility of routinely available haematological inflammatory ratios and lipid peroxidation biomarkers for phenotypic characterisation of MASLD in the diabetic context, highlighting the need for larger prospective studies with histological validation.<\/jats:p>","DOI":"10.3390\/ijms27125432","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:27:21Z","timestamp":1781666841000},"page":"5432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oxidative Stress Biomarkers and Systemic Inflammatory Indices in Metabolic Dysfunction-Associated Steatotic Liver Disease with Type 2 Diabetes Mellitus: A Comparative and Longitudinal Analysis"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-5689","authenticated-orcid":false,"given":"Vlad","family":"P\u0103dureanu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4817-1365","authenticated-orcid":false,"given":"Lidia","family":"Boldeanu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-7354","authenticated-orcid":false,"given":"Anca","family":"Bob\u00eerc\u0103","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Clenciu","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"P\u0103dureanu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Mitrea","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8853-5238","authenticated-orcid":false,"given":"Veronica","family":"Gheorman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0218tefan","family":"P\u0103tra\u0219cu","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Elena","family":"Vladu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Georgescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6133-4341","authenticated-orcid":false,"given":"Ionela Mihaela","family":"Vladu","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-7583","authenticated-orcid":false,"given":"Virginia Maria","family":"Radulescu","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"NAFLD Nomenclature Consensus Group (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol., 79, 1542\u20131556.","DOI":"10.1097\/HEP.0000000000000695"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: Updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes. Facts, 17, 374\u2013443. Erratum in Obes. Facts 2024, 17, 658. https:\/\/doi.org\/10.1159\/000541386.","DOI":"10.1159\/000539371"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: An updated systematic review and meta-analysis","volume":"72","author":"Cho","year":"2023","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111846","DOI":"10.1016\/j.diabres.2024.111846","article-title":"Diabetes as a risk factor for MASH progression","volume":"217","author":"Gancheva","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.15184","article-title":"Metabolic dysfunction-associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications","volume":"1538","author":"Fan","year":"2024","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, P., Lozano, P., Ros, G., and Solano, F. (2023). Hyperglycemia and oxidative stress: An integral, updated and critical overview of their metabolic interconnections. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119352"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Seidita, A., Cusimano, A., Giuliano, A., Meli, M., Carroccio, A., Soresi, M., and Giannitrapani, L. (2024). Oxidative stress as a target for non-pharmacological intervention in MAFLD: Could there be a role for EVOO?. Antioxidants, 13.","DOI":"10.3390\/antiox13060731"},{"key":"ref_10","unstructured":"Chekanov, A.V., Tikhaze, A.K., and Lankin, V.Z. (2021). Malondialdehyde as an endogenous aldehyde with important biological properties: Analysis of its metabolism and diagnostic value. Biomedicines, 9."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mignini, I., Galasso, L., Piccirilli, G., Calvez, V., Termite, F., Esposto, G., Borriello, R., Miele, L., Ainora, M.E., and Gasbarrini, A. (2024). Interplay of oxidative stress, gut microbiota, and nicotine in metabolic-associated steatotic liver disease (MASLD). Antioxidants, 13.","DOI":"10.3390\/antiox13121532"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1080\/13547500500216546","article-title":"F2-isoprostanes as markers of oxidative stress in vivo: An overview","volume":"10","author":"Milne","year":"2005","journal-title":"Biomarkers"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1554079","DOI":"10.1155\/2022\/1554079","article-title":"Prognostic role of neutrophil to lymphocyte ratio in nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"2022","author":"Shavakhi","year":"2022","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, A.H., Li, R.L., Li, W.J., Liu, Y., and Li, T. (2024). Association of neutrophil-to-lymphocyte ratio and risk of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: A population-based cohort study. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1499524"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3117396","DOI":"10.1155\/2023\/3117396","article-title":"The association between neutrophil-to-lymphocyte ratio and glycemic control in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"2023","author":"Adane","year":"2023","journal-title":"J. Diabetes Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, H., Zhou, Y., Wang, H., Zhang, M., Qiu, P., Zhang, M., Zhang, R., Zhao, Q., and Liu, J. (2020). Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01169"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Alabdulaali, B., Al-Rashed, F., Al-Onaizi, M., Kandari, A., Razafiarison, J., Tonui, D., Williams, M.R., Bl\u00e9riot, C., Ahmad, R., and Alzaid, F. (2023). Macrophages and the development and progression of non-alcoholic fatty liver disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1195699"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yan, C., Zhang, W., Xiao, Y., Sun, Y., Peng, X., and Cai, W. (2024). The predictive role of the platelet-to-lymphocyte ratio for the risk of non-alcoholic fatty liver disease and cirrhosis: A nationwide cross-sectional study. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1376894"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/MEG.0000000000002439","article-title":"The correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with nonalcoholic fatty liver disease: A cross-sectional study","volume":"34","author":"Zhou","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1373\/clinchem.2005.061408","article-title":"Biomarkers of oxidative damage in human disease","volume":"52","author":"Rossi","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Zelber-Sagi, S., Ivancovsky-Wajcman, D., Fliss-Isakov, N., Webb, M., Halpern, Z., Oren, R., and Shibolet, O. (2020). Serum malondialdehyde is associated with non-alcoholic fatty liver and related liver damage differentially in men and women. Antioxidants, 9.","DOI":"10.3390\/antiox9070578"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhu, N., Song, Y., Zhang, C., Wang, K., and Han, J. (2023). Association between the peripheral neutrophil-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1294425"},{"key":"ref_24","first-page":"273","article-title":"FIB-4 and platelet-related scores in advanced liver fibrosis risk assessment: Focus on MASLD and related conditions","volume":"18","author":"Nogueira","year":"2024","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am. J. Pathol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:33:31Z","timestamp":1781667211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125432"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125432","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}